My ePortfolio Register   

AACR 2014 /
I-SPY 2 trial shows promising development for some breast cancer patients using neratinib

5th - 9th Apr 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 16.04.14
Views: 2083

Dr John W. Park - University of California, San Francisco Hellen Diller Family Comprehensive Cancer Center, San Francisco, USA

At a press conference during AACR, Dr John Park discussed the findings surrounding the I-SPY 2 trial which identified a neo-adjuvant regimen containing the investigational drug neratinib, which may benefit HER 2 positive breast cancer patients in the future.

Read the article for more. 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence